We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
David Kaplan

David E. Kaplan MD, MSc, FACP, FAASLD

Associate Professor of Medicine, Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia; Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania

Dr. David E. Kaplan is an Associate Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania. He serves as Director of Hepatology at the Corporal Michael J. Crescenz Veterans Administration Medical Center, where he directs a regional hepatocellular carcinoma program.

Dr. Kaplan maintains a VA-funded translational research laboratory focusing on immunopathogenesis of hepatocellular carcinoma and the development of personalized medicine platforms for liver cancer therapy. He extensively collaborates with VA investigators in large database studies studying pharmaco-epidemiological associations in cirrhosis and hepatocellular carcinoma. He currently serves as chairperson of the AASLD Foundation Research Awards Committee.

Disclosures

Dr. David E. Kaplan has received research grants paid to his institution from Gilead Inc. and Bayer Healthcare Inc., the NIH and VA. He has received compensation for advisory board participation with Exelixis Inc.

Recent Contributions to PracticeUpdate:

  1. Effect of Statins on the Risk of Cholangiocarcinoma